Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Systematic Review Article

The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis

Author(s): Nur Atikah Razali, Hatta Sidi*, Chia Lip Choy, Nur Aishah Che Roos, Azlin Baharudin and Srijit Das

Volume 20, Issue 10, 2022

Published on: 23 May, 2022

Page: [1941 - 1955] Pages: 15

DOI: 10.2174/1570159X20666220222145735

Price: $65

Abstract

Although few clinical trials examined the efficacy of bupropion to treat sexual dysfunction among female patients, a comprehensive and objective synthesis of the best available evidence is still lacking. To date, to the best of our knowledge, there are no published systematic reviews or meta-analyses specifically focusing on the role of bupropion in the treatment of female sexual dysfunction. The main objective of the present study was to evaluate the efficacy of bupropion in the treatment of female sexual dysfunction, and we hypothesized that bupropion is efficient in treating female patients with sexual dysfunction. This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search for published literature was performed using Ovid, Medline, Scopus, Cochrane Library, Science Direct, and PubMed databases. In our study, we found that bupropion was almost three-fold more favorable in improving problems with sexual desire (pool estimate 2.845, 95% CI: 0.215 to 5.475, I2= 95.6%, p=0.034). A meta-regression was performed to explore heterogeneity and we found that only the dosage of bupropion was statistically significant in explaining the variance, i.e., the lower the dosage (150 mg vs. 300 mg), the better the improvement in the sexual desire of women with hypoactive sexual desire disorder (HSDD). Based on the results of this systematic review and metaanalysis, there is a potential role of bupropion as an effective treatment for women with HSDD.

Keywords: Female sexual dysfunction, treatment, bupropion, systematic review, PRISMA, HSDD.

Graphical Abstract
[1]
Basson, R.; Brotto, L.A.; Laan, E.; Redmond, G.; Utian, W.H. Assessment and management of women’s sexual dysfunctions: Problematic desire and arousal. J. Sex. Med., 2005, 2(3), 291-300.
[http://dx.doi.org/10.1111/j.1743-6109.2005.20346.x] [PMID: 16422860]
[2]
Basson, R.; Leiblum, S.; Brotto, L.; Derogatis, L.; Fourcroy, J.; Fugl-Meyer, K.; Graziottin, A.; Heiman, J.R.; Laan, E.; Meston, C.; Schover, L.; van Lankveld, J.; Schultz, W.W. Definitions of women’s sexual dysfunction reconsidered: Advocating expansion and revision. J. Psychosom. Obstet. Gynaecol., 2003, 24(4), 221-229.
[http://dx.doi.org/10.3109/01674820309074686] [PMID: 14702882]
[3]
Clayton, A.H.; Kingsberg, S.A.; Goldstein, I. Evaluation and management of hypoactive sexual desire disorder. Sex. Med., 2018, 6(2), 59-74.
[http://dx.doi.org/10.1016/j.esxm.2018.01.004] [PMID: 29523488]
[4]
Graziottin, A. Prevalence and evaluation of sexual health problems--HSDD in Europe. J. Sex. Med., 2007, 4(Suppl. 3), 211-219.
[http://dx.doi.org/10.1111/j.1743-6109.2007.00447.x] [PMID: 17394593]
[5]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Available from: https://www. psychiatry.org/psychiatrists/practice/dsm Retrieved on 16 December 2020.
[6]
Frances, A.; First, M.B.; Pincus, H.A. DSM-IV guidebook; American Psychiatric Association, 1995.
[7]
Segraves, R.T. Overview of sexual dysfunction complicating the treatment of depression. J. Clin. Psychiatry. Monogr, 1992, 10(2), 4-10.
[8]
Kavoussi, R.J.; Segraves, R.T.; Hughes, A.R.; Ascher, J.A.; Johnston, J.A. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J. Clin. Psychiatry, 1997, 58(12), 532-537.
[http://dx.doi.org/10.4088/JCP.v58n1204] [PMID: 9448656]
[9]
Chew, P.Y.; Choy, C.L.; Sidi, H.B.; Abdullah, N.; Che Roos, N.A.; Salleh Sahimi, H.M.; Abdul Samad, F.D.; Ravindran, A. The association between female sexual dysfunction and sexual dysfunction in the male partner: A systematic review and meta-analysis. J. Sex. Med., 2021, 18(1), 99-112.
[http://dx.doi.org/10.1016/j.jsxm.2020.10.001] [PMID: 33303390]
[10]
Portman, D.J.; Brown, L.; Yuan, J.; Kissling, R.; Kingsberg, S.A. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: Results of the PLUMERIA study. J. Sex. Med., 2017, 14(6), 834-842.
[http://dx.doi.org/10.1016/j.jsxm.2017.03.258] [PMID: 28583342]
[11]
Bloemers, J.; van Rooij, K.; de Leede, L.; Frijlink, H.W.; Koppeschaar, H.P.F.; Olivier, B.; Tuiten, A. Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: A pharmacokinetic comparison. Br. J. Clin. Pharmacol., 2016, 81(6), 1091-1102.
[http://dx.doi.org/10.1111/bcp.12887] [PMID: 26804967]
[12]
Stahl, S.M.; Pradko, J.F.; Haight, B.R.; Modell, J.G.; Rockett, C.B.; Learned-Coughlin, S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim. Care Companion J. Clin. Psychiatry, 2004, 6(4), 159-166.
[http://dx.doi.org/10.4088/PCC.v06n0403] [PMID: 15361919]
[13]
Modell, J.G.; May, R.S.; Katholi, C.R. Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: A pilot study. J. Sex Marital Ther., 2000, 26(3), 231-240.
[http://dx.doi.org/10.1080/00926230050084623] [PMID: 10929571]
[14]
Fava, M.; Rush, A.J.; Thase, M.E.; Clayton, A.; Stahl, S.M.; Pradko, J.F.; Johnston, J.A. 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prim. Care Companion J. Clin. Psychiatry, 2005, 7(3), 106-113.
[http://dx.doi.org/10.4088/PCC.v07n0305] [PMID: 16027765]
[15]
Rosen, R.C.; Lane, R.M.; Menza, M. Effects of SSRIs on sexual function: A critical review. J. Clin. Psychopharmacol., 1999, 19(1), 67-85.
[http://dx.doi.org/10.1097/00004714-199902000-00013] [PMID: 9934946]
[16]
Kennedy, S.H.; McCann, S.M.; Masellis, M.; McIntyre, R.S.; Raskin, J.; McKay, G.; Baker, G.B. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry, 2002, 63(3), 181-186.
[http://dx.doi.org/10.4088/JCP.v63n0302] [PMID: 11926715]
[17]
Segraves, R.T.; Clayton, A.; Croft, H.; Wolf, A.; Warnock, J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol., 2004, 24(3), 339-342.
[http://dx.doi.org/10.1097/01.jcp.0000125686.20338.c1] [PMID: 15118489]
[18]
Bolduan, A.J.; Haas, D.M. A systematic review of the use of bupropion for hypoactive sexual desire disorder in premenopausal women. J. Woman’s. Reprod. Heal, 2015, 1(1), 14-23.
[http://dx.doi.org/10.14302/issn.2381-862X.jwrh-14-546]
[19]
Page, M.J.; Moher, D.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; McKenzie, J.E. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ, 2021, 372, n160.
[http://dx.doi.org/10.1136/bmj.n160] [PMID: 33781993]
[20]
Safarinejad, M.R. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: A double-blind, placebo-controlled and randomized study. J. Psychopharmacol., 2011, 25(3), 370-378.
[http://dx.doi.org/10.1177/0269881109351966] [PMID: 20080928]
[21]
Safarinejad, M.R.; Hosseini, S.Y.; Asgari, M.A.; Dadkhah, F.; Taghva, A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int., 2010, 106(6), 832-839.
[http://dx.doi.org/10.1111/j.1464-410X.2010.09208.x] [PMID: 20151970]
[22]
Thase, M.E.; Clayton, A.H.; Haight, B.R.; Thompson, A.H.; Modell, J.G.; Johnston, J.A. A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. J. Clin. Psychopharmacol., 2006, 26(5), 482-488.
[http://dx.doi.org/10.1097/01.jcp.0000239790.83707.ab] [PMID: 16974189]
[23]
Clayton, A.H.; Warnock, J.K.; Kornstein, S.G.; Pinkerton, R.; Sheldon-Keller, A.; McGarvey, E.L. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry, 2004, 65(1), 62-67.
[http://dx.doi.org/10.4088/JCP.v65n0110] [PMID: 14744170]
[24]
Kennedy, S.H.; Fulton, K.A.; Bagby, R.M.; Greene, A.L.; Cohen, N.L.; Rafi-Tari, S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can. J. Psychiatry, 2006, 51(4), 234-242.
[http://dx.doi.org/10.1177/070674370605100405] [PMID: 16629348]
[25]
Hartmann, U.H.; Rüffer-Hesse, C.; Krüger, T.H.C.; Philippsohn, S. Individual and dyadic barriers to a pharmacotherapeutic treatment of hypoactive sexual desire disorders: Results and implications from a small-scale study with bupropion. J. Sex Marital Ther., 2012, 38(4), 325-348.
[http://dx.doi.org/10.1080/0092623X.2011.606495] [PMID: 22712818]
[26]
Dobkin, R.D.; Menza, M.; Marin, H.; Allen, L.A.; Rousso, R.; Leiblum, S.R. Bupropion improves sexual functioning in depressed minority women: An open-label switch study. J. Clin. Psychopharmacol., 2006, 26(1), 21-26.
[PMID: 16415700]
[27]
Segraves, R.T.; Croft, H.; Kavoussi, R.; Ascher, J.A.; Batey, S.R.; Foster, V.J.; Bolden-Watson, C.; Metz, A. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J. Sex Marital Ther., 2001, 27(3), 303-316.
[http://dx.doi.org/10.1080/009262301750257155] [PMID: 11354935]
[28]
Mathias, C.; Cardeal Mendes, C.M.; Pondé de Sena, E.; Dias de Moraes, E.; Bastos, C.; Braghiroli, M.I.; Nuñez, G.; Athanazio, R.; Alban, L.; Moore, H.C.; del Giglio, A. An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann. Oncol., 2006, 17(12), 1792-1796.
[http://dx.doi.org/10.1093/annonc/mdl304] [PMID: 16980597]
[29]
Gitlin, M.J.; Suri, R.; Altshuler, L.; Zuckerbrow-Miller, J.; Fairbanks, L. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J. Sex Marital Ther., 2002, 28(2), 131-138.
[http://dx.doi.org/10.1080/00926230252851870] [PMID: 11894796]
[30]
Basson, R. Women’s sexual dysfunction: Revised and expanded definitions. CMAJ, 2005, 172(10), 1327-1333.
[http://dx.doi.org/10.1503/cmaj.1020174] [PMID: 15883409]
[31]
Basson, R.; Leiblum, S.; Brotto, L.; Derogatis, L.; Fourcroy, J.; Fugl-Meyer, K.; Graziottin, A.; Heiman, J.R.; Laan, E.; Meston, C.; Schover, L.; van Lankveld, J.; Schultz, W.W. Revised definitions of women’s sexual dysfunction. J. Sex. Med., 2004, 1(1), 40-48.
[http://dx.doi.org/10.1111/j.1743-6109.2004.10107.x] [PMID: 16422982]
[32]
Basson, R. Using a different model for female sexual response to address women’s problematic low sexual desire. J. Sex Marital Ther., 2001, 27(5), 395-403.
[http://dx.doi.org/10.1080/713846827] [PMID: 11554199]
[33]
Sidi, H.; Naing, L.; Midin, M.; Nik Jaafar, N.R. The female sexual response cycle: Do Malaysian women conform to the circular model? J. Sex. Med., 2008, 5(10), 2359-2366.
[http://dx.doi.org/10.1111/j.1743-6109.2007.00653.x] [PMID: 18086161]
[34]
Ferris, R.M.; Cooper, B.R. Mechanism of antidepressant activity of bupropion. J. Clin. Psychiatry. Monogr, 1993, 11(1), 2-14.
[35]
Sadighparvar, S.; Tale, F.; Shahabi, P.; Naderi, S.; Ghaderi Pakdel, F. The response of ventral tegmental area dopaminergic neurons to bupropion: Excitation or inhibition? Basic Clin. Neurosci., 2019, 10(4), 281-304.
[PMID: 32231766]
[36]
Nutt, D.J.; Baldwin, D.S.; Clayton, A.H.; Elgie, R.; Lecrubier, Y.; Montejo, A.L.; Papakostas, G.I.; Souery, D.; Trivedi, M.H.; Tylee, A. Consensus statement and research needs: The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry, 2006, 67(Suppl. 6), 46-49.
[PMID: 16848678]
[37]
Fabre, L.F.; Brodie, H.K.; Garver, D.; Zung, W.W. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J. Clin. Psychiatry, 1983, 44(5 Pt 2), 88-94.
[PMID: 6406472]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy